KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
Japan · Delayed Price · Currency is JPY 1,530.00
+7.00 (0.46%)
Jul 31, 2025, 12:44 PM JST
KYORIN Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 130,087 | 119,532 | 113,270 | 105,534 | 102,904 | Upgrade | |
Revenue Growth (YoY) | 8.83% | 5.53% | 7.33% | 2.56% | -6.44% | Upgrade |
Cost of Revenue | 70,551 | 68,124 | 63,102 | 56,093 | 51,276 | Upgrade |
Gross Profit | 59,536 | 51,408 | 50,168 | 49,441 | 51,628 | Upgrade |
Selling, General & Admin | 36,453 | 37,375 | 34,140 | 35,536 | 36,138 | Upgrade |
Research & Development | 10,514 | 8,019 | 10,903 | 8,897 | 9,703 | Upgrade |
Operating Expenses | 46,989 | 45,402 | 45,047 | 44,437 | 45,853 | Upgrade |
Operating Income | 12,547 | 6,006 | 5,121 | 5,004 | 5,775 | Upgrade |
Interest Expense | -173 | -66 | -66 | -66 | -68 | Upgrade |
Interest & Investment Income | 497 | 500 | 465 | 410 | 420 | Upgrade |
Earnings From Equity Investments | 38 | -12 | - | 25 | 49 | Upgrade |
Currency Exchange Gain (Loss) | 165 | 59 | 78 | 98 | 129 | Upgrade |
Other Non Operating Income (Expenses) | 144 | 114 | 228 | 97 | 143 | Upgrade |
EBT Excluding Unusual Items | 13,218 | 6,601 | 5,826 | 5,568 | 6,448 | Upgrade |
Gain (Loss) on Sale of Investments | -305 | 1,403 | 70 | -320 | 488 | Upgrade |
Gain (Loss) on Sale of Assets | -127 | -90 | -15 | -32 | 342 | Upgrade |
Asset Writedown | - | - | -257 | - | - | Upgrade |
Other Unusual Items | -16 | -896 | 1,281 | - | 1,074 | Upgrade |
Pretax Income | 12,770 | 7,018 | 6,905 | 5,216 | 8,352 | Upgrade |
Income Tax Expense | 3,684 | 1,696 | 2,182 | 1,284 | 2,222 | Upgrade |
Net Income | 9,086 | 5,322 | 4,723 | 3,932 | 6,130 | Upgrade |
Net Income to Common | 9,086 | 5,322 | 4,723 | 3,932 | 6,130 | Upgrade |
Net Income Growth | 70.73% | 12.68% | 20.12% | -35.86% | -0.31% | Upgrade |
Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | Upgrade |
Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 57 | Upgrade |
Shares Change (YoY) | 0.10% | 0.15% | 0.00% | 0.01% | 0.02% | Upgrade |
EPS (Basic) | 158.16 | 92.73 | 82.42 | 68.62 | 106.99 | Upgrade |
EPS (Diluted) | 158.16 | 92.73 | 82.42 | 68.62 | 106.99 | Upgrade |
EPS Growth | 70.55% | 12.51% | 20.11% | -35.86% | -0.33% | Upgrade |
Free Cash Flow | -2,191 | -4,229 | -4,322 | 3,902 | 1,122 | Upgrade |
Free Cash Flow Per Share | -38.14 | -73.69 | -75.42 | 68.09 | 19.58 | Upgrade |
Dividend Per Share | 52.000 | 52.000 | 52.000 | 52.000 | 75.000 | Upgrade |
Dividend Growth | - | - | - | -30.67% | - | Upgrade |
Gross Margin | 45.77% | 43.01% | 44.29% | 46.85% | 50.17% | Upgrade |
Operating Margin | 9.64% | 5.03% | 4.52% | 4.74% | 5.61% | Upgrade |
Profit Margin | 6.98% | 4.45% | 4.17% | 3.73% | 5.96% | Upgrade |
Free Cash Flow Margin | -1.68% | -3.54% | -3.82% | 3.70% | 1.09% | Upgrade |
EBITDA | 17,150 | 10,296 | 8,961 | 8,718 | 9,339 | Upgrade |
EBITDA Margin | 13.18% | 8.61% | 7.91% | 8.26% | 9.07% | Upgrade |
D&A For EBITDA | 4,603 | 4,290 | 3,840 | 3,714 | 3,564 | Upgrade |
EBIT | 12,547 | 6,006 | 5,121 | 5,004 | 5,775 | Upgrade |
EBIT Margin | 9.64% | 5.03% | 4.52% | 4.74% | 5.61% | Upgrade |
Effective Tax Rate | 28.85% | 24.17% | 31.60% | 24.62% | 26.60% | Upgrade |
Advertising Expenses | 4,589 | 5,593 | 4,714 | 4,731 | 5,784 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.